Molecular synthesis and primary screening assay platform R&D for anti-COVID drug discovery and pre-clinical research

Our team has responded to the European Union's call for action against COVID-19.

We therefore commenced a European Regional Development Fund-backed project, "Molecular synthesis and primary screening assay platform R&D for anti-COVID drug discovery and pre-clinical research". 

The project is funded as part of the European Union's response to the COVID-19 pandemic.

Aim and objectives: The project financing is helping our team develop a novel integrated drug development platform (1), and use it to synthesise and field-test a potent SARS-CoV-2 MPro inhibitor (2).

Partners: delta biosciences took on the mission in partnership with Postera AI, a high-growth US startup leveraging machine learning to provide Medicinal Chemistry as a Service. 

Our collaboration is within the framework of an international open science, crowdsourced "COVID Moonshot" initiative to accelerate the development of a COVID antiviral. 

​

We are the first Lithuanian organisation to join the initiative and are thus also working to facilitate international scientific cooperation.

​

Duration: March 1st, 2021 - February 28th, 2022 (12 months)

​

About us: delta biosciences is prototyping an innovative workflow for early-stage drug discovery to help industry partners save time and resources. Our USP is vertical integration of the latest advances in bench sciences (microfluidic sorting, DNA-encoded libraries and NextGen Sequencing) and wide-ranging scientific expertise – compound synthesis (chemistry!), bioassay development (biology!), nano-engineering (physics!) and data science.